Thrombolysis of obstructed coronary arteries by intravenous administration of plasminogen
activators has become an established treatment of acute myocardial infarction (for review …

Objectives. The aim of this study was to determine the appropriate dose of a novel
recombinant tissue-type piasminogen activator (BM 06.022) for thrombolysis in patients with …

The novel recombinant plasminogen activator BM 06.022 consists of the kringle 2 and
protease domains of human tissue‐type plasminogen activator and is unglycosylated …

The thrombolytic and systemic effects of BM 06.022 were evaluated and compared with
those of alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary …

In a randomized, single-blind, placebo-controlled, cross-over Phase-I study pharmacokinetic
and hemostatic properties of BM 06.022 were investigated in seven healthy, male human …

Since currently available thrombolytics still show disadvantages, such as administration by
infusion, occurrence of intracranial hemorrhage, major hemorrhagic complications, allergic …

The novel recombinant plasminogen activator (rPA)(BM 06.022) is a mutant of tissue-type
plasminogen activator expressed in escherichia coli which can be given as a bolus because …

Synopsis Coronary arterial thrombolysis is becoming an established treatment of acute
myocardial infarction. If given early enough, it recanalises occluded coronary arteries …

Seventeen patients with acute transmural myocardial infarction and angiographically
confirmed complete coronary occlusion were treated with heparin combined with …

Streptokinase and urokinase have proved to be useful in a limited number of clinical
conditions. Mainly because of the risk and unpredictability of bleeding with this first …